CCP
MRNA icon

Corient Capital Partners’s Moderna MRNA Stock Holding History

Corient Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$786K Buy
5,500
+118
+2% +$17.9K 0.06% 253
2022
Q2 		$769K Buy
5,382
+763
+17% +$109K 0.06% 263
2022
Q1 		$796K Buy
4,619
+367
+9% +$61.8K 0.05% 287
2021
Q4 		$1.08M Buy
4,252
+270
+7% +$78.9K 0.07% 219
2021
Q3 		$1.53M Buy
3,982
+544
+16% +$201K 0.11% 170
2021
Q2 		$808K Buy
3,438
+521
+18% +$93.1K 0.06% 251
2021
Q1 		$382K Buy
2,917
+298
+11% +$43.2K 0.03% 380
2020
Q4 		$274K Buy
+2,619
New +$265K 0.03% 407

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Corient Capital Partners's MRNA Position: Q3 2022 in Review

Corient Capital Partners increased its Moderna (MRNA) stake by 2.2% in Q3 2022, buying an estimated $17.9K and bringing the position to 5,500 shares worth $786K. The position accounts for 0.06% of the portfolio, ranked #253.

Corient Capital Partners first reported a position in MRNA in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.53M in Q3 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Corient Capital Partners held 5,500 shares of Moderna worth $786K as of Q3 2022.
  • Corient Capital Partners bought 118 Moderna shares in Q3 2022, an estimated $17.9K.
  • Moderna made up 0.06% of Corient Capital Partners's portfolio in Q3 2022, its #253 holding.
  • Corient Capital Partners first reported a position in Moderna in Q4 2020 and has held it in 8 quarters since.
  • Corient Capital Partners's Moderna position peaked at $1.53M in Q3 2021.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.